Breast Cancer Clinical Trial
Official title:
A Multi-center, Double Blinded Randomized Controlled Trial Evaluating Closure of the Dead Space After Mastectomy Using Sutures or Tissue Glue Versus Conventional Closure. Protocol for the Seroma Reduction After Mastectomy (SAM) Trial
Rationale: Seroma formation and its sequelae form the mainstay of complications in breast
cancer surgery. Seroma has an incidence of 3% to 85%. Complications vary from delayed wound
healing, infection, skin flap necrosis, patient discomfort and repeated visits to the out
patient clinic. The key to reducing seroma formations seems to partly lie in the obliteration
of dead space. The use of electrocautery has been demonstrated to increase seroma formation
following mastectomy, however no other surgical devices (laser scalpel, argon diathermy and
ultrasonic scalpel) or substances have proven to be superior in seroma reduction.
No prospective randomized controlled trials have been able to demonstrate which techniques
are superior in reducing seroma and as a consequence patient discomfort in patients
undergoing mastectomy. In a previous retrospective observational study these investigators
demonstrated that mastectomy flap fixation significantly reduced seroma formation and the
number of seroma aspirations. In a pilot study that was recently performed in one of the
investigators hospitals, ARTISS tissue glue was used for skin flap fixation and showed
promising results. The investigators hypothesize that obliteration of the dead space
following mastectomy will significantly reduce seroma formation, its complications and the
discomfort it causes patients undergoing mastectomy.
1. INTRODUCTION AND RATIONALE
Seroma formation is a common side effect after surgery for breast cancer, with an
incidence of 3% to 85%. Seroma is a collection of serous fluid that contains blood
plasma and/ or lymph fluid. Some surgeons regard seroma formation as a necessary evil
after breast cancer surgery. Seroma formation and its sequelae form the mainstay of
complications in breast cancer surgery. Complications vary from delayed wound healing,
infection, skin flap necrosis, patient discomfort and repeated visits to the out patient
clinic to deal with seroma and its sequelae.
The key to reducing seroma formations seems to partly lie in the obliteration of dead
space. However, the techniques used to achieve this goal are subjects of much
controversy and debate. In a randomized controlled study it was difficult to elucidate
whether reducing the dead space or ligation of lymphatics or a combination of both were
responsible of reduction of seroma formation.
The use of electrocautery has been demonstrated to increase seroma formation following
mastectomy, however no other surgical devices (laser scalpel, argon diathermy and
ultrasonic scalpel) or substances have proven to be superior in seroma reduction. Seroma
formation after axillary dissection for breast cancer cannot be avoided but hopefully it
can be minimized by mechanical dead space closure. This systematic review highlights the
fact that seroma formation is multifactorial and prevention of seroma is difficult at
present. Certain prospective trials have been performed that demonstrate that flap
anchoring and therefore dead space reduction could be very beneficial. The trial
performed by Laurence et al analysed flap fixation and closed suction drainage. In this
study there was no difference in seroma rates, but patients without drains were
discharged earlier. In the trial performed by Sakkary et al the amount of fluid drained
was significantly less in the flap fixation group however patient discomfort (seroma
aspirations and out patient visits) were not assessed.
A Cochrane review was published in 2013 regarding Fibrin Glue (Tissuecol), Fibrin Glue
did not influence the incidence of postoperative seroma, the mean volume of seroma,
wound infections, complications and the length of hospital stays in people undergoing
breast cancer surgery. Due to significant methodological and clinical diversity among
the included studies this conclusion may be considered weak and biased. Therefore, a
major multicentre and high-quality RCT is required to validate these findings. ARTISS
tissue glue is a two-component fibrin sealant matrix of human fibrinogen and human
thrombin wich has the advantage of setting in 60 seconds. This means that the surgeon
has 60 seconds to correctly position the skin flaps before the tissue sealant sets,
The investigators hypothesize that obliteration of the dead space following mastectomy
will significantly reduce seroma formation. This study aims to reduce seroma formation
after mastectomy, proving that obliteration of dead space following mastectomy is vital
in preventing seroma formation and its sequelae.
The investigators current standard of treatment for patients undergoing mastectomy in
Atrium Medical Centre Heerlen is flap fixation using interrupted Vicryl sutures and
closed suction drainage. In Orbis Medical Centre Sittard current standard of wound
closure in patients undergoing mastectomy is ARTISS Tissue Glue.
A retrospective study (13-N-77) has been conducted in our centre in which flap fixation
seemed to be an effective surgical technique in reducing dead space and therefore seroma
formation in patients undergoing mastectomy for invasive breast cancer. Patients
undergoing flap fixation required fewer seroma aspirations and had fewer seroma related
complications (infection).
2. OBJECTIVES
Primary Objective:
To assess:
1. The number of seroma aspirations
Secondary Objective(s):
To assess:
1. The number of out patient clinic visits
2. Infection rate
3. Shoulder function
4. Cosmesis
5. Quality of life, costs and cost-effectiveness (cost/QALY)
3. STUDY DESIGN
Study design is a double-blind randomized controlled trial. All patients are > 18 years and
will be enrolled after obtaining informed consent in the surgical out patient clinics of
Zuyderland Medical Center (Heerlen and Sittard), Maastricht University Medical Center, St
Jans Gasthuis, Weert and Albert Schweitser Hospital, Dordrecht. All patients have an
indication to undergo mastectomy due to invasive breast cancer or DCIS.
Follow up will be performed until 1 year after surgery. Patients will be evaluated in the out
patient clinic 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively.
Study population:
Female patients > 18 years diagnosed with invasive breast cancer or DCIS with an indication
to perform mastectomy
Intervention:
1. Conventional mastectomy with closed suction drainage
2. Mastectomy with flap fixation using absorbable sutures and closed suction drainage
3. Mastectomy with flap fixation using ARTISS tissue glue and closed suction drainage
Main study parameters/endpoints:
Primary endpoint: Number of seroma aspirations
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: Patients will be informed about the study before inclusion in the out patient
clinic. Informed consent will be obtained in the out patient clinic a week after patients
were initially informed. Postoperative check ups will de done more frequently.
Standard postoperative check ups:
2 weeks, 3 months, 12 months
Additional study postoperative check ups:
6 weeks, 6 months Therefore patients will be required to undergo two additional check ups.
During out patients' visits, patients will hand in questionnaires regarding shoulder function
and a questionnaire scale regarding cosmesis.
Patients will be clinically examined as they usually would be.
Out-patient follow up identical for all three groups
2 weeks post operatively, DASH + cosmesis questionnaire, clinical assessment seroma 6 weeks
post operatively, DASH + cosmesis questionnaire + EQ-5D, clinical assessment seroma 3 months
post operatively, DASH + cosmesis questionnaire + EQ-5D + cost questionnaire, clinical
assessment seroma 6 months post operatively, DASH + cosmesis questionnaire + EQ-5D + cost
questionnaire, clinical assessment seroma 12 months post operatively, DASH + cosmesis
questionnaire +EQ-5D + cost questionnaire, clinical assessment seroma
EXIT FROM TRIAL 1 YEAR POST OPERATIVELY 4. STUDY POPULATION 4.1 Population (base ) All
patients will be recruited from the surgical breast cancer clinic after evaluation for
invasive breast cancer or DCIS. Patients will be recruited from two breast cancer clinics,
treating 500 patients annually for breast cancer. Patients undergoing mastectomy or modified
radical mastectomy are eligible for inclusion.
4.2 Inclusion criteria Older than 18 years Female sex Indication for mastectomy or modified
radical mastectomy
4.3 Exclusion criteria Patients undergoing breast conserving therapy Patients undergoing
direct breast reconstruction Unable to comprehend implications and extent of study and sign
for informed consent
4.4 Sample size calculation The number of seroma aspirations is not normally distributed.
Therefore, sample size estimations based on normally distributed continuous variables cannot
be used. It is possible to use formulas based on non-parametric analysis methods, estimating
the chance of a random patient in the treatment group having fewer aspirations than a random
patient in the control group. However, since the majority of patients will have the same
number of aspirations (i.e. 0), this method of sample size estimation does not seem to be
applicable to our study.
Sample size estimation based on ordinal regression is in line with the data distribution and
limited possibilities (maximum number of aspirations in the observational retrospective study
was 4) of the outcome variable (Walters SJ. Health Qual Life Outcomes 2004: 2(1); 26). Using
alpha=0.025 (correction for 2 comparisons with 3 study groups), beta=0.10, and a proportional
odds ratio=2.67 (corresponding to an absolute difference of 20% in the need for seroma
punctions), the sample size is estimated at 112 patients per study group.
5. TREATMENT OF SUBJECTS Group 1: conventional treatment and closed suction drainage Group 2:
flap fixation with vicryl sutures and closed suction drainage Group 3: Artiss tissue glue and
closed suction drainage
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |